by: Parent Project Muscular DystrophyDirect Access: Sarepta, eteplirsen with Chris Garabedian (October 2012)
On October 23, PPMD hosted a webinar with Sarepta to discuss of the 48 Week dystrophin and 6-minute walk test (6MWT) data from the Phase IIb extension study in Duchenne as well as next steps for the eteplirsen program. Chris Garabedian, President and CEO of Sarepta Therapeutics presented the data and answered submitted questions.
